Avelumab/Axitinib Approved: Advanced Renal Cell Carcinoma

​The FDA has approved avelumab (Bavencio®, EMD Serono, Inc.) in combination with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for advanced renal cell carcinoma (RCC). Avelumab is an anti–programmed death ligand 1 (anti–PD-L1) antibody, a type of immune checkpoint inhibitor. Axitinib, a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI), improves tumor infiltration by immune cells. It has antiangiogenic activity, meaning that it prevents tumors from gro...
Continue reading

New First-Line Treatment in Metastatic Renal Cell Carcinoma

Pembrolizumab (Keytruda®, Merck Inc.), previously FDA approved for various cancers, including advanced non-small cell lung cancer, classical Hodgkin lymphoma, and advanced gastric cancer, has now been granted FDA approval to be administered in conjunction with axitinib (Inlyta®, Pfizer Inc.) as first-line treatment for patients with locally advanced or metastatic renal cell carcinoma (RCC). As an immunotherapy drug, pembrolizumab fights cancer by working with the patient's immune system. The dru...
Continue reading

Advanced Renal-Cell Carcinoma: Potential First-Line Treatment

​A phase 3 clinical trial has found that in previously untreated patients with advanced renal-cell carcinoma (RCC), avelumab plus axitinib improves progression-free survival and objective response compared with sunitinib. Sunitinib is an antiangiogenic drug, meaning that it prevents tumors from growing their own blood vessels. It is considered standard of care as a first-line therapy for patients with advanced RCC. However, many patients either have inherent resistance to antiangiogenic drugs or...
Continue reading

Advances in the Personalized Management of RCC With Brian I. Rini, MD, FACP

Based on recent estimates, kidney cancer accounts for approximately 4% of all cancer diagnoses in the United States. An estimated 65,300 new cases are reported each year and more than 14,000 people die of the disease. Renal cell carcinoma (RCC), which comprises nearly 90% of all kidney cancers, is characterized by a lack of early warning signs, diverse clinical manifestations, and resistance to radiation and chemotherapy. As a result of its often asymptomatic presentation, many patients present ...
Continue reading

New Protein Mimics Interleukin 2 Sans Side Effects

Researchers have used a computer program to design a protein that mimics the action of interleukin 2 (IL-2) and interleukin 15 (IL-15) without the toxic side effects. Interleukin 2 (IL-2), a cytokine that regulates the activities of the immune system's white blood cells, is a powerful anti-cancer drug used to treat metastatic melanoma and renal cell carcinoma. However, its toxic side effects, such as impairment of kidney function, have limited its use as a cancer-fighting agent. "People have tri...
Continue reading

Subscribe

Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.